Navigation path

Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information


EU orphan designation number: EU/3/17/1948   
Active ingredient: 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl
Indication: Treatment of familial cerebral cavernous malformations
Sponsor: Premier Research Group Limited
1st Floor, Rubra 2, Mulberry Business Park, Fishponds Road, Wokingham, Berkshire RG41 2GY, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
14/12/2017 Orphan designation EMA/OD/135/17 (2017)8780 of 12/12/2017